Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20801354 | 1.00 | PSMB8 (0.36) | PSMB8HSD11B1 | |
| SCHEMBL24859945 | 1.00 | PSMB8 (0.36) | PSMB8HSD11B1 | |
| SCHEMBL20801358 | 1.00 | PSMB8 (0.36) | PSMB8HSD11B1 | |
| SCHEMBL22180992 | 1.00 | PSMB8 (0.36) | PSMB8HSD11B1 | |
| SCHEMBL24860103 | 1.00 | PSMB8 (0.36) | PSMB8HSD11B1 | |
| SCHEMBL20801415 | 0.87 | PSMB8 (0.39) | PSMB8HSD11B1 | |
| SCHEMBL410465 | 0.84 | PSMB8 (0.32) | PSMB8 | |
| SCHEMBL19658247 | 0.84 | PSMB8 (0.32) | PSMB8 | |
| SCHEMBL19658254 | 0.84 | PSMB8 (0.32) | PSMB8 | |
| SCHEMBL17776321 | 0.84 | PSMB8 (0.32) | PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218824-A2 | IMMUNOCONJUGATE SYNTHESIS METHOD | Bolt Biotherapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885HSD11B1 2578/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | PSMB8 2177/4885HSD11B1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.